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Abstract
Objective: To study the effectiveness and tolerability of antiepileptic drugs (AEDs) 
commonly used in juvenile myoclonic epilepsy (JME).
Methods: People with JME were identified from a large database of individuals with 
epilepsy, which includes detailed retrospective information on AED use. We assessed 
secular changes in AED use and calculated rates of response (12‐month seizure free-
dom) and adverse drug reactions (ADRs) for the five most common AEDs. Retention 
was modeled with a Cox proportional hazards model. We compared valproate use 
between males and females.
Results: We included 305 people with 688 AED trials of valproate, lamotrigine, lev-
etiracetam, carbamazepine, and topiramate. Valproate and carbamazepine were most 
often prescribed as the first AED. The response rate to valproate was highest among 
the five AEDs (42.7%), and significantly higher than response rates for lamotrigine, 
carbamazepine, and topiramate; the difference to the response rate to levetiracetam 
(37.1%) was not significant. The rates of ADRs were highest for topiramate (45.5%) 
and valproate (37.5%). Commonest ADRs included weight change, lethargy, and 
tremor. In the Cox proportional hazards model, later start year (1.10 [1.08‐1.13], 
P < 0.001) and female sex (1.41 [1.07‐1.85], P = 0.02) were associated with shorter 
trial duration. Valproate was associated with the longest treatment duration; trials with 
carbamazepine and topiramate were significantly shorter (HR [CI]: 3.29 [2.15‐5.02], 
P < 0.001 and 1.93 [1.31‐2.86], P < 0.001). The relative frequency of valproate tri-
als shows a decreasing trend since 2003 while there is an increasing trend for leveti-
racetam. Fewer females than males received valproate (76.2% vs 92.6%, P = 0.001).
Significance: In people with JME, valproate is an effective AED; levetiracetam 
emerged as an alternative. Valproate is now contraindicated in women of childbear-
ing potential without special precautions. With appropriate selection and safeguards 
in place, valproate should remain available as a therapy, including as an alternative 
for women of childbearing potential whose seizures are resistant to other treatments.
K E Y W O R D S
seizures, tolerability, adverse drug reactions, valproate
1 |  INTRODUCTION
Juvenile myoclonic epilepsy (JME) is a common epilepsy 
syndrome, comprising 5%‐10% of all epilepsies.1 As JME 
tends to start during adolescence and lifestyle issues are 
known to increase the likelihood of seizures, particular atten-
tion and care are often required.2‒4 Sodium valproate has long 
been the antiepileptic drug (AED) of choice for treatment of 
people with JME, with reported seizure freedom attained in up 
to 80%.5 Despite its effectiveness, valproate use is limited by 
adverse drug reactions (ADRs), teratogenicity, and neurotox-
icity,6,7 with important recent restrictions on its use in women 
of childbearing potential.8 Newer AEDs are taking an increas-
ing role in the management of JME, but there are few data 
on comparative effectiveness to guide treatment choices.3,9‒12
Key Points
• We conducted a retrospective study of compara-
tive effectiveness of five commonly used antiepi-
leptic drugs in 305 individuals with JME
• Valproate was associated with the highest re-
sponse rate; levetiracetam ranked second
• Topiramate and valproate were associated with 
highest rates of ADRs
• Controlling for start year and sex, valproate was 
associated with the longest treatment duration
• Valproate should remain available as a treatment 
option for people with refractory JME irrespective 
of sex
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People with JME comprised a quarter of those with idio-
pathic generalized epilepsy (IGE) in the SANAD study, which 
demonstrated the effectiveness of valproate in IGE overall.13 
In a retrospective study of 962 individuals with IGE, of whom 
357 had JME, valproate monotherapy was associated with a 
higher response rate compared to lamotrigine or topiramate, 
but no statistical comparison was undertaken.9 Three previ-
ous studies have addressed AED comparative effectiveness in 
JME specifically. These include a prospective study of 156 
people10 and a retrospective study of 186 individuals11; sta-
tistical testing of differences between AED effectiveness was 
not reported in either study.10,11 In another retrospective study 
of 72 individuals, trials with valproate, lamotrigine, or topira-
mate were associated with better control of myoclonic seizures 
compared to trials involving phenytoin or carbamazepine.12
The prognosis of JME is relatively good with a re-
ported remission rate of approximately 60%,14 but a sub-
set of individuals is refractory to appropriate medical 
treatment.4,5,14,15 While AED withdrawal without seizure 
recurrence may be successful in some,14 the majority of 
people in remission remain on AEDs,14,15 raising concerns 
about long‐term side effects. More information regarding 
the effectiveness and tolerability of AEDs in JME is re-
quired. Our aim was to evaluate AED frequency of use, 
effectiveness, retention, and tolerability in a real‐world set-
ting. Despite limitations imposed by its observational and 
retrospective nature, our study provides some much‐needed 
data on this important topic.
2 |  METHODS
2.1 | Participants
People with JME were identified from a large clinical database 
from the EpiPGX consortium, an international multicenter re-
search project on epilepsy pharmacogenetics (www.epipgx.
eu). This database contains demographic and clinical details of 
nearly 10,000 people with a confirmed diagnosis of epilepsy 
and detailed information on more than 39,000 treatment regi-
mens (hereafter referred to as trials), all collected retrospectively 
from medical records. Participants were recruited mainly from 
tertiary referral centers. Data collection was started in 2012 and 
completed in 2016. Data collection and use was approved by 
research ethical committees/institutional review boards of each 
center, and all participants provided written informed consent 
for appropriately coded use of their clinical data.
The ascertainment of JME cases was based on the crite-
ria of the International League Against Epilepsy (ILAE) and 
an international consensus statement2,16: (a) occurrence of 
myoclonic seizures, (b) onset between age 8‐25 years, (c) no 
evidence of progressive disease or intellectual disability, (d) 
EEG showing generalized epileptiform activity (cases with 
normal EEG during appropriate AED treatment were in-
cluded, if deemed to otherwise fulfill criteria for JME by the 
treating specialist), (e) no clinically significant abnormality 
on neuroimaging, where available.
We identified 321 individuals recruited from specialized 
epilepsy clinics in Belgium, Germany, Ireland, Italy, the 
Netherlands, the United Kingdom, and Australia (see Table 
S1 for details). Among them, 12 (3.7%) had already been in-
cluded in the SANAD study.13 All AED trials from the time 
of epilepsy diagnosis were considered, including those in-
troduced as add‐on therapy, with some exclusions: (a) AED 
trials started less than one year before the last clinic visit and 
(b) AEDs used in fewer than 50 trials. Prescription order, 
however, was determined considering all AED trials of the 
individual (see Figure 1). Both regular and extended release 
AED formulations were included in the analyses.
2.2 | Outcome measure definition
The classification of AED trial outcomes was modified from 
the ILAE consensus.17 Response was determined clinically as 
seizure freedom, lasting for ≥12  months, attributable to the 
AED according to either the treating clinician or the person un-
dertaking phenotyping, or both, and occurring prior to initiation 
of another treatment for epilepsy. Failure of a trial of treatment 
was defined as persistent seizures at >50% of the pretreatment 
seizure frequency despite use of an appropriate AED with an 
adequate trial. We applied the ILAE criteria for assessing ad-
equacy of an intervention.17 To aid outcome assessment, re-
searchers performing the phenotyping used the World Health 
Organization (WHO) defined daily doses for each AED, as well 
as the summary table from the ILAE consensus paper defin-
ing the minimum dataset to determine whether an intervention 
is informative.17 If data were available but neither criteria for 
response nor failure were met, the outcome was considered un-
classified. If the data required for assessing outcome were miss-
ing, the response was categorized as “unknown” (this included 
trials which were stopped before the outcome was known). 
Population percentage response was calculated as the number 
of responses divided by the total number of known outcomes 
(response, failure, and unclassified). For trials ongoing at last 
follow‐up, treatment duration was calculated based on the date 
of last visit, if available. In total, treatment duration was defined 
for 527 AED trials. Twelve‐month retention rate was defined as 
the proportion of trials with minimum duration of 12 months. 
The reason for discontinuation was recorded as due to ADR, 
lack of effectiveness, ADR and lack of effectiveness, other rea-
son, remission, or unknown. ADRs were classified into nine 
categories, and their incidence was calculated for each AED 
as percentage of all trials. Only ADRs considered attribut-
able to the specific AED either by the treating clinician and/or 
person undertaking phenotyping, or both, were included. The 
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maximum daily dose was recorded for AED trials. Valproate 
trials were stratified by maximum daily dosage ≤1 g and >1 g, 
in keeping with classification used in previous literature.18
2.3 | Statistical analyses
Median values were used to express central tendency for 
durations of trials as data were not normally distributed. 
Pairwise comparisons with χ2 analyses were performed to 
compare the AEDs with respect to population percentage 
response rates and rates of ADRs. Similarly, we compared 
the proportions of females and males receiving valproate, the 
number of valproate trials between females and males, and 
the response rates among first, second, or third or later order 
AED trials. Bonferroni correction for multiple comparisons 
was applied. We report corrected P‐values for simplicity; 
values ≤0.05 were considered significant.
We modeled discontinuation patterns and compared re-
tention of different AEDs with a Cox proportional hazards 
model. The outcome measure was trial duration, with haz-
ard ratios presenting hazard of shorter duration. The co-
factors included were AED (five levels, one for each AED, 
with valproate considered the reference level), trial start 
year (as a continuous variable), and sex (with male sex con-
sidered the default). Trial start year and sex were included 
as we hypothesized that these could influence retention. 
The global test for nonproportionality was not significant; 
thus, the Cox model could be applied.
The Mann‐Whitney U test was used to compare maximum 
daily dose distributions of valproate between trials associated 
with response and trials associated with failure. All analyses 
were performed using R.19
3 |  RESULTS
Three hundred and five individuals were included in the final 
analyses (1). The most commonly used AEDs were valproate, 
FIGURE 1 Flowchart for inclusion of people and AED trials. The number of trials for which defined data were available is indicated for each parameter
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lamotrigine, levetiracetam, carbamazepine, and topiramate, 
constituting 688 trials (Table 2). Other AEDs were each used 
in fewer than 50 trials and were excluded from further analy-
ses (see Table S2 and Figure S1 for further demographic and 
clinical details). Valproate and carbamazepine most often con-
stituted first‐order AED trials, whereas lamotrigine was most 
commonly started as the second AED trial, levetiracetam as the 
third trial, and topiramate as the fourth trial (see Tables S3‐S4).
3.1 | Secular patterns of AED trials
The first AED trial in the study was started in June 1968 and the 
last in March 2014. The highest number of trials was recorded 
in 2003 and 2005, with 206 trials in each. Secular changes in the 
prevalence of AED trials are presented in Figure 2. Since 2003, 
there has been a decline in the absolute and relative frequency 
of valproate trials. During this time, the relative frequency of 
lamotrigine trials remained stable while the relative frequency 
of levetiracetam trials increased. The majority of carbamaz-
epine trials took place in the 1990s, with only individual trials 
recorded from 2005 onwards. See Figure S2 for sex‐specific 
secular changes in the relative frequencies of AED trials.
3.2 | Effectiveness
Response rates to AEDs ranged from 14.1% (carbamaz-
epine) to 42.7% (valproate); see Figure 3 and Table S5 for 
further details. The population percentage response rate to 
valproate was significantly higher than the population per-
centage response rate to lamotrigine (P < 0.001), carbamaz-
epine (P = 0.03), and topiramate (P = 0.02). The differences 
in population percentage response rates between other AED 
pairs were not significant (Table S6).
For individual AEDs, correlation between response rate 
and prescription order could not be performed due to the 
relatively low response rates observed. Considering all five 
AEDs together, the response rate of first‐order AED trials 
was highest (first: 45.6%, second: 38.8% and third or later: 
30.0%), but the differences were not statistically significant.
3.3 | Drug retention
Twelve‐month retention rates ranged from 62.7% for topira-
mate to 86.1% for valproate; valproate also had the highest 
median treatment duration (Table 2, Figure S3). In the Cox 
model, a significant effect of start year on trial duration was 
observed; later start year was associated with shorter trial du-
ration (HR [CI]: 1.10 [1.08‐1.13], P  <  0.001). Female sex 
was associated with shorter trial duration (1.41 [1.07‐1.85], 
P = 0.02). The hazard ratios comparing the duration of the 
other AEDs to valproate, after adjusting for effect of start 
year and sex, are presented in Figure S4. Compared to val-
proate, carbamazepine and topiramate were associated with 
significantly shorter trial durations.
3.4 | AED discontinuation
A reason for discontinuation was noted for 69.0% of trials. 
Lamotrigine had the highest rate of discontinuation due to 
lack of effectiveness (40.8% of trials), but a low rate of dis-
continuation due to ADRs (10.2%). The respective figures 
for levetiracetam were 25.4% and 14.9%. Topiramate was as-
sociated with the highest rate of discontinuation due to ADRs 
(24.5%) (Table S7).
3.5 | Adverse drug reactions
The frequency of ADRs ranged from 14.5% for carbamazepine 
to 45.5% for topiramate. The rate of ADRs for carbamazepine 
was significantly lower than the rate of ADRs for topiramate 
(P = 0.005) and valproate (P = 0.010). The rate of ADRs for la-
motrigine was also significantly lower than that for topiramate 
(P < 0.001) and valproate (P < 0.001). Overall, the three most 
common ADRs were weight change (reported in 64 trials), leth-
argy (40 trials), and tremor (37 trials). The incidence of specific 
ADRs, however, varied for each AED (see Table 3). Additional 
information on ADRs is presented in Appendix S1.
3.6 | Valproate dosage and use in 
males and females
Of the 119 valproate trials associated with response, 61 (51.3%) 
involved a maximum daily dose of ≤1 g. In trials associated 
T A B L E  1  Demographic and clinical details
Category  
Age (y) Mean Range
At last visit 31 13‐78
At epilepsy diagnosis 16 8‐43
At onset 15 8‐25
Epilepsy duration (y) 15 1‐65
AED trials per patient 2 1‐8
  Total number Percentage (%)
Sex
Male 95 31.1
Female 210 68.9
Seizure type
GTCS 267 87.5
Absence 92 30.2
Myoclonic 305 100
Note: Abbreviations: AED, antiepileptic drug; GTCS, generalized tonic‐clonic 
seizures.
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with response, the median maximum daily dose was 1000 mg/d, 
whereas for failed trials, it was 1500 mg/d. The difference in the 
maximum daily dose distributions was statistically significant 
(Mann‐Whitney P = 0.004; see Figure S5).
Valproate was trialed in 92.6% of males and 76.2% of females; 
the difference was significant (P  =  0.001). Females more fre-
quently had interruption of valproate treatment, with more than 
one valproate trial in 13.8% of females versus 10.2% of males.
F I G U R E  2  The secular prevalence of AED trials between 1968 and 2014. The extreme right vertical line indicates the 2013 recommendation 
by the UK Medicines and Healthcare products Regulatory Agency to restrict valproate use, and referral of valproate to the European Medicines 
Agency Pharmacovigilance Risk Assessment Committee36
F I G U R E  3  Relative frequencies of trial outcomes for each AED
8 |   SILVENNOINEN Et aL.
4 |  DISCUSSION
We explored the use of AEDs in 305 people with JME over 
a long period, providing observational real‐world insight into 
the tolerability and effectiveness of AEDs in this syndrome. 
The topic is timely as means of managing risks of valproate 
have recently undergone review by the European Medicines 
Agency,8 with important implications for management of 
JME. Prospective JME‐specific trials involving the current 
array of AEDs, including valproate, are now very unlikely, 
and observational studies such as ours provide important in-
formation for clinical practice. Compared to previous JME‐
specific studies,10‒12 a strength of our study is a relatively 
large number of trials with AEDs other than valproate, for-
mal comparative testing, and stringent criteria for JME diag-
nostic ascertainment. We applied a uniform method of data 
collection in all centers; data were stored in a single database. 
Recently, we successfully applied the same strategy for in-
vestigating AED use in mesial temporal lobe epilepsy.20
An obvious weakness of our study is its retrospective design: 
We could not account for possible effects of the natural history 
of JME on outcomes. Patients were gathered mainly from ter-
tiary centers, which should increase confidence in the validity 
of syndromic diagnosis.21 Individuals with refractory epilepsy 
may, however, be overrepresented in our sample. Other JME 
studies report a female preponderance.15 In our study, the more 
pronounced gender difference may further reflect referral bias 
to our tertiary centers, related, for example, to management is-
sues around pregnancy or family planning. Observed patterns 
of AED use may be biased by local practices at the participat-
ing centers. EpiPGX was not designed to look prospectively at 
neurodevelopmental outcomes in children exposed to AEDs in 
utero, and we cannot comment on this very important topic. 
Lastly, classifying drug response is challenging, with various 
schemes: We chose a modification of the ILAE scheme.17 The 
ILAE definition of seizure freedom requires that duration of 
seizure freedom is three times the previous interseizure in-
terval (“Rule of Three”) or at least 12 months, whichever is 
longer.17 The limitations of the “Rule of Three” for prediction 
of ongoing seizure freedom are, however, recognized.22 The 
conventional definition based only on at least 12 months' sei-
zure freedom is still commonly used.23 The ILAE definition of 
treatment failure is lack of seizure freedom after an informative 
trial of an intervention17; for clinical utility, we defined failure 
as less than 50% reduction in seizure frequency.
The frequencies of trials for individual AEDs are in-
fluenced by changes in AED availability over time. The 
predominance of valproate was expected considering its 
long‐standing availability and typical practice having been to 
use it as first‐line treatment for JME.24 Carbamazepine, which 
is not recommended for treatment of JME,3 emerged as the 
fourth most commonly tried AED. In over half of these trials, 
carbamazepine was the first AED tried. Most carbamazepine TA
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trials in our sample date to the 1990s, when fewer treatment 
options were available. In some individuals, carbamazepine 
trials may also have predated their JME diagnosis.
The response rate to valproate was the highest, and the 
population percentage response rate differed significantly 
from that of lamotrigine, carbamazepine, and topiramate. 
Levetiracetam had the second highest response rate with no 
significant difference compared to valproate. Effectiveness 
measures may be affected by prescription order25; most trials 
with levetiracetam were the individual's third or later order 
AED trial. The comparison of response rates is limited by 
lack of data on whether an AED was introduced as monother-
apy or as add‐on. This would have been particularly inter-
esting for valproate and lamotrigine, given the evidence for 
synergism between these AEDs.26 Further limitations are the 
high frequencies of unclassified and unknown outcomes. We 
lacked effectiveness information for specific seizure types; 
we expect that this may impact upon rating for absence and 
myoclonic seizures especially. According to previous reports, 
carbamazepine and lamotrigine are associated with risk of 
more frequent myoclonic seizures,3,27 but we were unable 
to assess whether this could have affected our outcomes. 
Nevertheless, our results are in keeping with prospective data 
on the high effectiveness of valproate in the management of 
IGE.13 They also indicate levetiracetam as an effective alter-
native, in keeping with previous reports of effectiveness of le-
vetiracetam as add‐on treatment28 or monotherapy29 in JME.
Pseudoresistance, that is treatment failure caused by life-
style factors such as alcohol consumption and sleep depriva-
tion, is a recognized concept in JME.4 As a further limitation, 
we were unable to assess whether such factors contributed to 
our treatment outcomes.
Valproate was associated with the highest 12‐month reten-
tion rate and median treatment duration. In our survival anal-
ysis, valproate was associated with a significantly longer trial 
duration compared to carbamazepine or topiramate, but not 
lamotrigine or levetiracetam. Retention parameters may be 
skewed by older trials started when fewer alternative AEDs 
were available. This was confirmed in the survival analysis. 
Another possible source of bias is the effect of prescription 
order, as an individual's first AED trial is more likely to be 
successful,25 and therefore have longer duration, compared to 
subsequent trials. In our sample, valproate most commonly 
constituted an individual's first trial.
The highest rate of ADRs was observed for topiramate, 
with valproate ranking second. For both AEDs, rates of ADRs 
were similar to those observed in SANAD.13 While there is 
some evidence that topiramate may be better tolerated than 
valproate as monotherapy for JME,30 our contrasting findings 
may reflect effects of polytherapy.31 Due to the retrospective 
nature of our study, some types of ADRs may have been more 
frequently recorded than others. The commonest ADR to 
topiramate was cognitive impairment, whereas for valproate, 
weight change was most common. These findings are gen-
erally in keeping with prospectively collected data.13,32 The 
commonest ADR to levetiracetam was behavioral disorder, 
and indeed concerns have been previously raised about the 
neuropsychiatric side effects of levetiracetam and topiramate 
in people with JME,33 in whom psychiatric comorbidities and 
impulsive personality traits appear overrepresented.34
No valproate dose is considered safe in pregnancy, but 
some risks associated with fetal exposure to valproate are 
known to be dose‐dependent,6 as are some of the valproate‐
associated ADRs.7 Recommended maintenance doses for 
valproate are 1‐2  g/d.35 There are suggestions that daily 
monotherapy doses of ≤1  g are sufficient for maintaining 
seizure freedom for a significant proportion of people with 
JME.10,18 In our group, over half of successful valproate trials 
involved maximum doses of 1 g/d. Together with previous re-
ports, our findings suggest that in people with JME for whom 
valproate is a necessary and appropriate treatment choice, it 
is reasonable to aim initially for lower doses.
Valproate is being superseded by other AEDs (see Figure 
2). The onset of this change in 2003 precedes the more re-
cent regulatory and pharmacovigilance measures,8,36 and 
likely reflects the combination of accumulating evidence 
of adverse outcomes in valproate‐associated pregnancies6 
and increasing availability of alternative AEDs. We also 
observed sex differences in the patterns of valproate use: 
Males were significantly more likely to receive valproate 
than females, and females' valproate trials were more likely 
to be subject to interruptions. These findings are in keeping 
with population‐based reports of decline in valproate use in 
treatment of epilepsy in women.37 While these observations 
reflect serious concern over adverse effects, teratogenicity, 
and risk of neurodevelopmental disorders in exposed off-
spring,6 they also suggest that people with JME, especially 
female, may be deprived of the most effective treatment for 
their condition, a concern already voiced by others.11 Poor 
seizure control carries well‐recognized risks,38 and it is im-
portant to consider the possible effects of reduced valproate 
use on seizure control and other outcomes in JME. Current 
restrictions on valproate use8 warrant a re‐assessment of 
therapeutic options for JME. Valproate was associated with 
a considerable rate of ADRs, and its potential for terato-
genicity and inducing neurodevelopmental disorders has 
significant implications for patient choice, counseling and 
treatment monitoring. Data on pregnancy‐related risks as-
sociated with valproate use have been widely disseminated 
again recently,8 and new measures for their management 
are in place. In girls and women, valproate use must take 
these new measures into account.8 Among other AEDs, our 
results corroborate the role of levetiracetam in the man-
agement of JME. Based on its high retention and response 
rates, however, valproate should remain available, with the 
necessary counseling and safeguards, as an alternative for 
10 |   SILVENNOINEN Et aL.
people not responsive to other treatments, irrespective of 
sex.
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